SCHEMBL1469142

SCHEMBL1469142

Cc1nc(C(=O)Nc2c[nH]c3ncc(Br)c(F)c23)cs1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
TLR7 Q9NYK1 3/20 0.41
GRM7 Q14831 1/20 0.39
GRM4 Q14833 1/20 0.39
KDM4E B2RXH2 1/20 0.38
PIK3CD O00329 3/20 0.38
SLC6A3 Q01959 1/20 0.37
KCNH2 Q12809 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
WDR5 P61964 1/20 0.36
IRAK4 Q9NWZ3 1/20 0.35
PIK3CA P42336 1/20 0.35
PIK3CB P42338 1/20 0.35
PIK3CG P48736 1/20 0.35
GSK3B P49841 1/20 0.35
DYRK1A Q13627 1/20 0.35
BACE1 P56817 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1467791 0.81 NPC1 (0.51) MAPTTDP1KDM4ENPC1RAB9A
SCHEMBL1468837 0.81 NPC1 (0.50) MAPTNPC1RAB9AKMT2A
SCHEMBL1467965 0.80 BACE1 (0.38) NPC1RAB9AIRAK4GSK3BDYRK1A
SCHEMBL1468908 0.80 NPC1 (0.48) MAPTTLR7GRM4NPC1RAB9A
SCHEMBL1468970 0.79 HTT (0.46) MAPTKDM4ENPC1RAB9AKMT2A
SCHEMBL1469049 0.77 BRD4 (0.40) TDP1SLC6A3KCNH2TAAR1NPC1
SCHEMBL1469369 0.77 RXFP1 (0.35) NPC1RAB9ADYRK1A
SCHEMBL1468895 0.76 SMN1; SMN2 (0.49) MAPTKDM4ENPC1RAB9A
SCHEMBL1467850 0.76 MAPT (0.40) MAPTGRM4KDM4EIRAK4KMT2A
SCHEMBL1468942 0.76 HDAC1 (0.47) MAPTTDP1KDM4EGSK3BKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9969727-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2018-05-15 US disclosed
US-20160368916-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2016-12-22 US disclosed
US-9365568-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2016-06-14 US disclosed
EP-2990407-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2016-03-02 EP disclosed
US-20150322061-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2015-11-12 US disclosed
EP-2307409-B1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC (US) 2015-08-12 EP disclosed
US-8981085-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2015-03-17 US disclosed
US-20140243520-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-08-28 US disclosed
US-8758830-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-06-24 US disclosed
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2014-04-10 US disclosed
US-8545897-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2013-10-01 US disclosed
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2013-02-21 US disclosed
US-8178131-B2 Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC. (US) 2012-05-15 US disclosed
CN-102089307-A Pyrrolopyridines as kinase inhibitors ARRAY BIOPHARMA INC 2011-06-08 CN disclosed
EP-2307409-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Array Biopharma, Inc. (US) 2011-04-13 EP disclosed
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2011-03-24 US disclosed
WO-2009140320-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2009-11-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243520-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A MAPT 3686/4885TDP1 88/4885TLR7 4676/4885
US-20160368916-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A MAPT 3686/4885TDP1 88/4885TLR7 4676/4885
US-20140100369-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A MAPT 3686/4885TDP1 88/4885TLR7 4676/4885
US-20110070317-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, BUB1B MAPT 3579/4885TDP1 184/4885TLR7 4734/4885
US-20150322061-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A MAPT 3686/4885TDP1 88/4885TLR7 4676/4885
US-20130045286-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS CHEK2, CHEK1, CDKN1A MAPT 3686/4885TDP1 88/4885TLR7 4676/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.